Professor Isozaki Hideko
Faculty, Affiliation
Cancer Research Institute Genome Biology
Professor
College and School Educational Field
Division of Medical Sciences, Graduate School of Medical Science
Division of Nano Life Science, Graduate School of Frontier Science Initiative
Division of Medicine, Graduate School of Medical Science
Division of Nano Life Science, Graduate School of Frontier Science Initiative
School of Medicine, College of Medical, Pharmaceutical and Health Sciences
Laboratory
Genome Biology TEL:076-264-6743
Academic Background
【Academic background(Doctoral/Master's Degree)】
Okayama University Doctor Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Hematology Oncology Respiratory Medicine / Clinical Pharmacy 200203 Completed
【Academic background(Bachelor's Degree)】
Setsunan University Pharmaceutics 200203
【Degree】
Medicine
Career
Kanazawa University Cancer Research Institute Professor(2024/11-)
Massachusetts General Hospital Cancer Center Harvard Medical School Instructor(2022/06-2024/09)
Massachusetts General Hospital Cancer Center Harvard Medical School Postdoctoral research fellow(2017/06-2022/05)
Okayama University Hospital Biobank Research coordinator(2017/02-2017/05)
Okayama University Graduate School of Medicine , Dentistry and Pharmaceutical Sciences Researcher(2014/04-2017/01)
Okayama University Hospital Pharmacy Pharmacist(2002/04-2014/03)
Year & Month of Birth
Academic Society
American Association for Cancer Research (AACR), Women in Cancer Research (WICR)
American Association for Cancer Research (AACR)
Japanese Lung Cancer Society
Japanese Society of Medical Oncology
International Association for the Study of Lung Cancer (IASLC)
Japanese Cancer Association (JCA)
European Society for Medical Oncology
Award
○Travel Grant Award(2015)
○Presentation Award(2015)
○Publication Award(2023)
○Pilot Grant Program Award(2020)
○Postdoctoral Fellowship Award(2020)
○Okayama Medical Association Award(2016)
○JCA Scholar-in-Training Award(2016)
○Young Investigator Award(2016)
Specialities
Speciality Keywords
Lung cancer,Cancer drug resistance,APOBEC,Genome Biology,Cancer evolution,Hereditary Breast and Ovarian Cancer (HBOC)
Research Themes
Books
Papers
- A novel molecular target, superoxide dismutase 1, in ALK inhibitor-resistant lung cancer cells, detected through proteomic analysis. Noriko Miyake,Nobuaki Ochi,Masami Takeyama,Hideko Isozaki,Eiki Ichihara,Hiromichi Yamane,Takuya Fukazawa,Yasunari Nagasaki,Tatsuyuki Kawahara,Hidekazu Nakanishi,Akio Hiraki,Katsuyuki Kiura,Nagio Takigawa Experimental cell research 442 2 114266 2024/10/01
- MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC. Naoki Haratake,Hiroki Ozawa,Yoshihiro Morimoto,Nami Yamashita,Tatsuaki Daimon,Atrayee Bhattacharya,Keyi Wang,Ayako Nakashoji,Hideko Isozaki,Mototsugu Shimokawa,Chie Kikutake,Mikita Suyama,Asato Hashinokuchi,Kazuki Takada,Tomoyoshi Takenaka,Tomoharu Yoshizumi,Tetsuya Mitsudomi,Aaron N Hata,Donald Kufe Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 19 3 434 2024/03
- Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Hideko Isozaki,Ramin Sakhtemani,Ammal Abbasi,Naveed Nikpour,Marcello Stanzione,Sunwoo Oh,Adam Langenbucher,Susanna Monroe,Wenjia Su,Heidie Frisco Cabanos,Faria M Siddiqui,Nicole Phan,Pégah Jalili,Daria Timonina,Samantha Bilton,Maria Gomez-Caraballo,Hannah L Archibald,Varuna Nangia,Kristin Dionne,Amanda Riley,Matthew Lawlor,Mandeep Kaur Banwait,Rosemary G Cobb,Lee Zou,Nicholas J Dyson,Christopher J Ott,Cyril Benes,Gad Getz,Chang S Chan,Alice T Shaw,Justin F Gainor,Jessica J Lin,Lecia V Sequist,Zofia Piotrowska,Beow Y Yeap,Jeffrey A Engelman,Jake June-Koo Lee,Yosef E Maruvka,Rémi Buisson,Michael S Lawrence,Aaron N Hata Nature 620 7973 393 2023/08
- Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial. Daijiro Harada,Hideko Isozaki,Toshiyuki Kozuki,Toshihide Yokoyama,Hiroshige Yoshioka,Akihiro Bessho,Shinobu Hosokawa,Ichiro Takata,Nagio Takigawa,Katsuyuki Hotta,Katsuyuki Kiura Thoracic cancer 12 5 643 2021/03
- Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Zofia Piotrowska,Hideko Isozaki,Jochen K Lennerz,Justin F Gainor,Inga T Lennes,Viola W Zhu,Nicolas Marcoux,Mandeep K Banwait,Subba R Digumarthy,Wenjia Su,Satoshi Yoda,Amanda K Riley,Varuna Nangia,Jessica J Lin,Rebecca J Nagy,Richard B Lanman,Dora Dias-Santagata,Mari Mino-Kenudson,A John Iafrate,Rebecca S Heist,Alice T Shaw,Erica K Evans,Corinne Clifford,Sai-Hong I Ou,Beni Wolf,Aaron N Hata,Lecia V Sequist Cancer discovery 8 12 1529 2018/12
- Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). Hideko Isozaki,Katsuyuki Hotta,Eiki Ichihara,Nagio Takigawa,Kadoaki Ohashi,Toshio Kubo,Takashi Ninomiya,Kiichiro Ninomiya,Naohiro Oda,Hiroshige Yoshioka,Hirohisa Ichikawa,Masaaki Inoue,Ichiro Takata,Takuo Shibayama,Shoichi Kuyama,Keisuke Sugimoto,Daijiro Harada,Shingo Harita,Toshiaki Sendo,Mitsune Tanimoto,Katsuyuki Kiura Clinical lung cancer 17 6 602 2016/11
- Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer. Nobuaki Ochi,Hideko Isozaki,Masami Takeyama,Jack W Singer,Hiromichi Yamane,Yoshihiro Honda,Katsuyuki Kiura,Nagio Takigawa Experimental cell research 344 2 194 2016/06/10
- Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. Hideko Isozaki,Eiki Ichihara,Nagio Takigawa,Kadoaki Ohashi,Nobuaki Ochi,Masayuki Yasugi,Takashi Ninomiya,Hiromichi Yamane,Katsuyuki Hotta,Katsuya Sakai,Kunio Matsumoto,Shinobu Hosokawa,Akihiro Bessho,Toshiaki Sendo,Mitsune Tanimoto,Katsuyuki Kiura Cancer research 76 6 1506 2016/03/15
- Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model. Daisuke Minami,Nagio Takigawa,Yuka Kato,Kenichiro Kudo,Hideko Isozaki,Shinsuke Hashida,Daijiro Harada,Nobuaki Ochi,Masanori Fujii,Toshio Kubo,Kadoaki Ohashi,Akiko Sato,Takehiro Tanaka,Katsuyuki Hotta,Masahiro Tabata,Shinichi Toyooka,Mitsune Tanimoto,Katsuyuki Kiura Cancer science 106 10 1296 2015/10
- Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. Hiromichi Yamane,Hideko Isozaki,Masami Takeyama,Nobuaki Ochi,Kenichiro Kudo,Yoshihiro Honda,Tomoko Yamagishi,Toshio Kubo,Katsuyuki Kiura,Nagio Takigawa American journal of cancer research 5 4 1553 2015
- Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. Hideko Isozaki,Nagio Takigawa,Katsuyuki Kiura Cancers 7 2 763 2015/04/30
- A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene. Hideko Isozaki,Masayuki Yasugi,Nagio Takigawa,Katsuyuki Hotta,Eiki Ichihara,Akihiko Taniguchi,Shinichi Toyooka,Shinsuke Hashida,Toshiaki Sendo,Mitsune Tanimoto,Katsuyuki Kiura Japanese journal of clinical oncology 44 10 963 2014/10
Conference Presentations
- APOBEC Pathway in Tumor Evolution and Drug Tolerance(conference：IASLC Hot Topic in Basic and Translational Science Meeting 2024)(2024/12)
Others
- Therapy-induced APOBEC3A drives evolution of persistent cancer cells Experimental Medicine 42 1 2024/01
Arts and Fieldwork
Patent
Theme to the desired joint research
Grant-in-Aid for Scientific Research
○International Jpint Research Acceleration Fund, JSPS「Role of Innate-immunity in cancer evolution」(2025-2027)
Competitive research funding,Contribution
○Impact of APOBEC in Hereditary Cancer Evolution JIKOCHOKOKU PROJECT, Kanazawa University Kanazawa University(2024-2026)